| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Pre-exposure prophylaxis for HIV prevention: how to predict success.
|
Lancet
|
2011
|
5.34
|
|
2
|
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
|
AIDS
|
2007
|
4.89
|
|
3
|
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
|
Ann Intern Med
|
2014
|
3.48
|
|
4
|
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.
|
J Acquir Immune Defic Syndr
|
2009
|
2.32
|
|
5
|
Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.
|
J Infect Dis
|
2011
|
1.70
|
|
6
|
The pharmacokinetics and viral activity of tenofovir in the male genital tract.
|
J Acquir Immune Defic Syndr
|
2008
|
1.55
|
|
7
|
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
|
J Acquir Immune Defic Syndr
|
2006
|
1.40
|
|
8
|
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
|
J Acquir Immune Defic Syndr
|
2013
|
1.20
|
|
9
|
Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV.
|
Environ Mol Mutagen
|
2007
|
1.03
|
|
10
|
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
|
Antimicrob Agents Chemother
|
2009
|
1.01
|
|
11
|
Evaluation of the repertoire of the TonB-dependent receptors of Haemophilus ducreyi for their role in virulence in humans.
|
J Infect Dis
|
2008
|
0.94
|
|
12
|
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
|
Clin Pharmacokinet
|
2012
|
0.91
|
|
13
|
Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment.
|
HIV Clin Trials
|
2013
|
0.91
|
|
14
|
Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.
|
Antivir Ther
|
2013
|
0.89
|
|
15
|
Models for predicting effective HIV chemoprevention in women.
|
J Acquir Immune Defic Syndr
|
2015
|
0.87
|
|
16
|
Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.
|
J Acquir Immune Defic Syndr
|
2012
|
0.87
|
|
17
|
"I should know better": the roles of relationships, spirituality, disclosure, stigma, and shame for older women living with HIV seeking support in the South.
|
J Assoc Nurses AIDS Care
|
2014
|
0.87
|
|
18
|
Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.
|
J Acquir Immune Defic Syndr
|
2013
|
0.84
|
|
19
|
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.
|
Antivir Ther
|
2016
|
0.81
|
|
20
|
Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
|
Antimicrob Agents Chemother
|
2006
|
0.78
|
|
21
|
Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.
|
Antivir Ther
|
2015
|
0.77
|
|
22
|
Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
|
Antivir Ther
|
2015
|
0.75
|
|
23
|
Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
24
|
Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200.
|
J Acquir Immune Defic Syndr
|
2010
|
0.75
|
|
25
|
Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.
|
J Acquir Immune Defic Syndr
|
2015
|
0.75
|